MicroRNA-325 (miR-325)

MicroRNA-325 (miR-325) is an endogenous, non-coding RNA molecule approximately 22 nucleotides in length, classified as a microRNA. It is located on the short arm of the X chromosome and acts as a post-transcriptional regulator by binding to target mRNAs and inhibiting their translation or promoting degradation. miR-325 targets at least 20 protein-coding genes and is implicated in multiple biological processes, including regulation of cell cycle, proliferation, apoptosis, epithelial-mesenchymal transition, invasion, and migration. It operates as part of complex regulatory networks, interacting with both circular and long non-coding RNAs as competing endogenous RNAs (ceRNAs). Aberrant expression of miR-325 is associated with cancers across nervous, endocrine, respiratory, reproductive, and digestive systems, and correlates with clinical outcomes and drug resistance to agents such as oxaliplatin, cisplatin, and doxorubicin. In the nervous system, miR-325-3p is highly expressed in neural stem cells and astrocytes, regulating apoptosis and potentially influencing neurogenesis and neurodegeneration. Because its dysregulation is involved in disease progression and therapeutic resistance, miR-325 is considered a promising therapeutic target and potential biomarker in oncology and neurology[1][2][3][4].

Other names

hsa-mir-325MIRN325MIR325microRNA-325-3p

Regulation of drug resistance via modulation of protein-coding gene expression; suppression or promotion of apoptosis and cell proliferation via direct mRNA targeting